Expanded enrollment into Phase II trial of MVI-816

Madison Vaccines has announced expanded enrollment of patients in the Phase II trial of its lead product candidate: MVI-816 (also known as pTVG-HP). MVI-816 is an immunotherapeutic agent that is being tested in locally progressive forms of prostate cancer after first-line therapy. … READ MORE …

New prostate cancer “vaccine” in Phase II trial prior to ADT

According to a media release we saw this morning, a company called Madison Vaccines has started a Phase II clinical trial of a new form of immunotherapy for treatment of men with non-metastatic prostate cancer and rising PSA levels prior to any treatment with androgen deprivation therapy (ADT). … READ MORE …